FDA 483 - Bavarian Nordic Berna GmbH

An FDA inspection of PaxVax Berna GmbH in Thörishaus, Switzerland, revealed significant deficiencies in quality control and manufacturing practices. Observations included inadequate investigations into foreign material and out-of-specification results, insufficient cleaning validation for freeze dryers, and poor oversight of adverse event reporting. These issues indicate potential risks to product quality and patient safety.